Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29616489 | 1.00 | IDO1 (0.59) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL75416 | 0.88 | IDO1 (0.46) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL28763543 | 0.84 | IDO1 (0.56) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL1538597 | 0.83 | IDO1 (0.63) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL3278241 | 0.81 | IDO1 (0.61) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL14774588 | 0.81 | IDO1 (0.56) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL17864241 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL109671 | 0.79 | IDO1 (0.65) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL195156 | 0.79 | KDM1A (0.43) | IDO1SLC6A4GPR183 | |
| SCHEMBL8417818 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024153946-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2024-07-25 | — | — | WO | disclosed |
| US-20240239775-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | BEIJING BEST PATHWAY MANAGEMENT CONSULTING CENTER (LIMITED PARTNERSHIP) (CN) | 2024-07-18 | — | — | US | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1140930-A1 | DIBENZO a,g]QUINOLIZINIUM DERIVATIVES AND THE SALTS THEREOF | HANWHA CHEMICAL CORPORATION (KR) | 2001-10-10 | — | — | EP | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000037468-A1 | DIBENZO[a,g]QUINOLIZINIUM DERIVATIVES AND THE SALTS THEREOF | HANWHA CHEMICAL CORPORATION (KR) | 2000-06-29 | — | — | WO | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6030979-A | INHIBITS THE STEROL 14-REDUCTASE WHICH CATALYZES THE BIOSYNTHESIS OF CHOLESTEROL FROM LANOSTEROL; ANTICHOLESTEROL AND-LIPEMIC AGENTS | HANWHA CORPORATION (CN) | 2000-02-29 | — | — | US | disclosed |
| US-6028197-A | ENZYME INHIBITORS INHIBITING THE STEROL 14-REDUCTASE WHICH IS INVOLVED IN THE DISTAL PATHWAY OF CHOLESTEROL BIOSYNTHESIS, AND THE USE AS ANTICHOLESTEROL AGENTS OR ANTILIPEMIC AGENTS | HANWHA CORPORATION (KR) | 2000-02-22 | — | — | US | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | IDO1 1452/4885SLC6A2 371/4885SLC6A4 1062/4885 |
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | IDO1 2935/4885SLC6A2 3959/4885SLC6A4 4399/4885 |
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | IDO1 225/4885SLC6A2 45/4885SLC6A4 238/4885 |
| US-20240239775-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | SLC10A1, NR1H4, FXR1 | IDO1 3516/4885SLC6A2 1113/4885SLC6A4 573/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | IDO1 225/4885SLC6A2 45/4885SLC6A4 238/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | IDO1 315/4885SLC6A2 85/4885SLC6A4 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.